News | August 06, 2025
Cadila Pharmaceuticals launches Vasograin Plus for treatment of migraines
Vasograin Plus represents a major advancement in the treatment of migraine
Vasograin Plus represents a major advancement in the treatment of migraine
The company reported a 28% year-on-year increase in Q2 revenue to Rs. 220.9 crore
The performance was below anticipated levels, primarily due to external factors such as seasonal disruption that affected overall results
India Formulation sales accounted for 34.2% of total consolidated sales for the quarter
Fermenta now becomes one of the only two companies globally to hold a CEP for this variant of Vitamin D3
Our specialty chemical businesses have continued to perform strongly, growing double digit YoY
Aman holds a bachelor’s degree in economics from Boston University and an MBA from Columbia University, New York
Dr. Rao has over 29 years of experience in manufacturing, R&D, business operations, and customer service
Net profit doubled to Rs. 10.8 crore, with PAT margin expanding by 560 bps to 14.3%, reflecting strong operational execution
This GMP certification for our sterile drug product manufacturing facility, Goa Plant II is a testament to our relentless efforts to supply quality and affordable medicines across geographies
Subscribe To Our Newsletter & Stay Updated
